Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 3/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL566636 | 1.00 | HPGD (0.61) | HPGDALDH1A1SMN1; SMN2NISCHHTT | |
| SCHEMBL29437007 | 1.00 | HPGD (0.61) | HPGDALDH1A1SMN1; SMN2NISCHHTT | |
| SCHEMBL1300333 | 1.00 | HPGD (0.61) | HPGDALDH1A1SMN1; SMN2NISCHHTT | |
| Hydrochloric Acid SCHEMBL7526056 | 0.98 | HPGD (0.59) | HPGDALDH1A1SMN1; SMN2NISCHHTT | |
| Hydrochloric Acid SCHEMBL7528728 | 0.98 | HPGD (0.59) | HPGDALDH1A1SMN1; SMN2NISCHHTT | |
| Hydrochloric Acid SCHEMBL3885955 | 0.98 | HPGD (0.59) | HPGDALDH1A1SMN1; SMN2NISCHHTT | |
| SCHEMBL29615516 | 0.95 | HPGD (0.56) | HPGDALDH1A1SMN1; SMN2NISCHHTT | |
| SCHEMBL3568567 | 0.86 | HPGD (0.63) | HPGDALDH1A1SMN1; SMN2NISCHHTT | |
| SCHEMBL1567597 | 0.85 | HPGD (0.61) | HPGDALDH1A1SMN1; SMN2NISCHHTT | |
| SCHEMBL30946854 | 0.85 | NISCH (0.71) | HPGDALDH1A1SMN1; SMN2NISCHHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 625 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551465-B2 | Pharmaceutical composition for treatment of hypertrophic cardiomyopathy and treatment method using same composition | CELLTRION INC. (KR) | 2026-02-17 | — | — | US | claimed |
| US-12104106-B2 | Compositions of chiral molecules and perovskite nanocrystals and methods of making the same | ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) | 2024-10-01 | — | — | US | claimed |
| US-11999741-B2 | Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | CARDURION PHARMACEUTICALS, INC. (US) | 2024-06-04 | — | — | US | claimed |
| CN-117105931-A | Method for preparing pyridopyrimidine compounds and intermediate thereof | 上海翰森生物医药科技有限公司 | 2023-11-24 | — | — | CN | claimed |
| CN-117004679-A | Molecular evolution and catalytic synthesis of (S) -1, 4-benzodioxane by candida antarctica lipase B | 上海交通大学 | 2023-11-07 | — | — | CN | claimed |
| US-20230190708-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY AND TREATMENT METHOD USING SAME COMPOSITION | CELLTRION, INC. (KR) | 2023-06-22 | — | — | US | claimed |
| US-20230122169-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | CELLTRION, INC. (KR) | 2023-04-20 | — | — | US | claimed |
| EP-4140482-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY AND TREATMENT METHOD USING SAME COMPOSITION | Celltrion, Inc. (KR) | 2023-03-01 | — | — | EP | claimed |
| CN-115297858-A | Pharmaceutical composition for treating hypertrophic cardiomyopathy and treatment method using same | 赛特瑞恩股份有限公司 | 2022-11-04 | — | — | CN | claimed |
| US-20220326082-A1 | CHIRAL HETEROSTRUCTURES | Alliance for Energy Innovation, LLC | 2022-10-13 | — | — | US | claimed |
| US-6608200-B1 | Saponification and amidation of ethyl-2,3-dihydrobenzo(1,4)-dioxin-2-carboxylate with piperazine; purification | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2003-08-19 | — | — | US | claimed |
| US-6500835-B2 | FOR PROPHYLAXIS AND THERAPY OF FIBROSIS INVOLVING EXTRACELLULAR MATRIX DYSBOLISM HAVING A CHYMASE INHIBITOR AS AN EFFECTIVE INGREDIENT; SIDE EFFECT REDUCTION | SUNTORY LIMITED (JP) | 2002-12-31 | — | — | US | claimed |
| US-20020119977-A1 | Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use related applications | NICOX S.A. (FR) | 2002-08-29 | — | — | US | claimed |
| EP-1222182-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) DIHYDROBENZOFURANS AND BENOZOPYRANS | Aventis Pharmaceuticals Inc. (US) | 2002-07-17 | — | — | EP | claimed |
| EP-0833937-B1 | OPTICAL RESOLUTION OF ALKYL 1,4-BENZODIOXAN-2-CARBOXYLATES USING ESTERASE FROM SERRATIA MARCESCENS | SEPRACOR INC (US) | 2002-01-23 | — | — | EP | claimed |
| WO-2001014358-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) DIHYDROBENZOFURANS AND BENOZOPYRANS | AVENTIS PHARMACEUTICALS INC. (DE) | 2001-03-01 | — | — | WO | claimed |
| EP-0833937-A1 | OPTICAL RESOLUTION OF ALKYL 1,4-BENZODIOXAN-2-CARBOXYLATES USING ESTERASE FROM SERRATIA MARCESCENS | Seprachem, Inc. (US) | 1998-04-08 | — | — | EP | claimed |
| WO-1996040976-A1 | OPTICAL RESOLUTION OF ALKYL 1,4-BENZODIOXAN-2-CARBOXYLATES USING ESTERASE FROM SERRATIA MARCESCENS | SEPRACHEM, INC. (US) | 1996-12-19 | — | — | WO | claimed |
| US-5529929-A | USING AQUEOUS SOLUTION OF MICROBIAL ESTERASE | SEPRACHEM, INC. (US) | 1996-06-25 | — | — | US | claimed |
| EP-0138358-A1 | The preparation and use of 2-[2-(1,4-benzodioxanyl)]-2-imidazoline in therapy | Farmos-Yhtyma Oy (FI) | 1985-04-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119977-A1 | Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use related applications | PTGS2, PTGES2, PTGES | HPGD 24/4885ALDH1A1 643/4885SMN1; SMN2 4345/4885 |
| US-11999741-B2 | Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | CDK8, PRMT8, RPS8 | HPGD 2516/4885ALDH1A1 2636/4885SMN1; SMN2 1150/4885 |
| US-12551465-B2 | Pharmaceutical composition for treatment of hypertrophic cardiomyopathy and treatment method using same composition | ME2, TNNT2, TNNC1 | HPGD 213/4885ALDH1A1 440/4885SMN1; SMN2 413/4885 |
| US-20230122169-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | SDHA, SDHB, ALDH5A1 | HPGD 256/4885ALDH1A1 230/4885SMN1; SMN2 2138/4885 |
| US-20230190708-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY AND TREATMENT METHOD USING SAME COMPOSITION | ATP2A2, CPT1B, TNNT2 | HPGD 1156/4885ALDH1A1 1793/4885SMN1; SMN2 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.